Fig. 5
From: MZ1 co-operates with trastuzumab in HER2 positive breast cancer
Identification of transcription factors downregulated with the combination. a p Value vs Hazard Ratio graph indicating transcription factors altered after combination treatment at 12, 24 h or both. Relapse Free Survival (RFS) for HER2+ status on the online tool Kaplan-Meier plotter was applied. Genes with no association prognosis value (p > 0.05) are shown in black. b Expression level heat map of the transcription factors identified (HOXB7, MEIS2, TCERG1, DNAJC2) after 12 and/or 24 h of treatment with MZ1, trastuzumab, and combination. c, mRNA expression levels of transcription factor identified genes after 12 or 24 h of treatment with the MZ1, trastuzumab, and combination. *p < 0.05; **p < 0.01; ***p < 0.005. d Kaplan-Meier survival plots of the combined selected genes (HOXB7, MEIS2, TCERG1, DNAJC2) signature expression level and patient prognosis in RFS and HER2+ status conditions